| Species |
Cynomolgus |
| Protein Construction |
TRAIL R2/DR5/TNFRSF10B (Ile58-Ser212)
Accession # A0A2K5TXK0 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized TRAIL R2/DR5/TNFRSF10B, His, Cynomolgus at 1μg/ml (100μl/well) on the plate can bind AntiTRAIL R2 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
18.28 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 25-35 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
DR5, also called TRAIL R2, TRICK 2, TNFRSF10B, and MK is a type 1 TNF R superfamily, membrane protein which is a receptor for TRAIL (APO2 ligand). DR5 is a receptor for the cytotoxic ligand TNFSF10/TRAIL. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. |
| Synonyms |
CD262; DR5; DR5TRICK2B; Fas-like protein; KILLER/DR5; TNFRSF10B; TRAIL R2; TRAIL receptor 2; TRAILR2; TRICK2; TRICK2A; TRICKB; ZTNFR9; KILLER |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
